Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Abstract Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. Ca...

Full description

Bibliographic Details
Main Authors: Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf, A. Kate Sasser
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Experimental Hematology & Oncology
Subjects:
Daratumumab
Immune response
Multiple myeloma
Stringent complete response
Sustained response
T-cell expansion
Online Access:http://link.springer.com/article/10.1186/s40164-018-0096-7

Internet

http://link.springer.com/article/10.1186/s40164-018-0096-7

Similar Items